Ponatinib Therapy for Philadelphia-Positive ALL (Ph+ ALL) Patients: Real-World Clinical Practice vs the PACE Trial

The pivotal phase 2 PACE trial (NCT01207440) evaluated ponatinib in adult patients with refractory Ph+ ALL. Prescribing data for US patients from January 2014 are available from the specialty pharmacy, Biologics, Inc.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research